Biogen and Eisai unveil real-world data confirming high long-term LEQEMBI persistence
Share
Biogen (NASDAQ:BIIB) and Eisai, today released new real-world findings from a massive U.S. claims analysis demonstrating high long-term persistence rates for patients receiving intravenous (IV) LEQEMBI® (lecanemab).
